Savior Lifetec Cash Flow Conversion Efficiency
Savior Lifetec cash flow conversion efficiency. Based on the latest financial reports, Savior Lifetec (4167) has a cash flow conversion efficiency ratio of -0.026x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$-98.65 Million ≈ $-3.11 Million USD) by net assets (NT$3.78 Billion ≈ $119.12 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Savior Lifetec (2011–2025)
Cash flow conversion efficiency of Savior Lifetec from 2011 to 2025. This chart illustrates how Savior Lifetec's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Savior Lifetec stock price for real-time trading data and today's change.
Savior Lifetec Cash Flow Conversion Ratio Explained
Savior Lifetec cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Savior Lifetec Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Savior Lifetec ranked by their cash flow conversion efficiency. Also see 4167 market cap overview for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Action S.A.
WAR:ACT
|
0.059x |
|
Aofu Environmental Technology Co Ltd
SHG:688021
|
0.022x |
|
HLB Pharmaceutical Co. Ltd
KQ:047920
|
0.015x |
|
Amcil Ltd
AU:AMH
|
0.008x |
|
Young Fast Optoelectronics Co Ltd
TW:3622
|
0.016x |
|
Akwel SA
PA:AKW
|
0.048x |
|
OBI Pharma
TWO:4174
|
-0.132x |
|
Winton Land Ltd
AU:WTN
|
-0.019x |
Annual Cash Flow Conversion Efficiency for Savior Lifetec (2011–2025)
The table below shows the annual cash flow conversion efficiency of Savior Lifetec from 2011 to 2025. Review 4167 free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | NT$3.78 Billion ≈ $119.12 Million |
NT$-21.04 Million ≈ $-662.91K |
-0.006x | -103.77% |
| 2024-12-31 | NT$3.52 Billion ≈ $110.78 Million |
NT$518.38 Million ≈ $16.33 Million |
0.147x | +27.87% |
| 2023-12-31 | NT$3.36 Billion ≈ $106.01 Million |
NT$387.95 Million ≈ $12.22 Million |
0.115x | -33.27% |
| 2022-12-31 | NT$3.37 Billion ≈ $106.08 Million |
NT$581.77 Million ≈ $18.33 Million |
0.173x | +440.04% |
| 2021-12-31 | NT$3.31 Billion ≈ $104.37 Million |
NT$-168.34 Million ≈ $-5.30 Million |
-0.051x | -285.45% |
| 2020-12-31 | NT$3.33 Billion ≈ $104.92 Million |
NT$91.25 Million ≈ $2.87 Million |
0.027x | -61.21% |
| 2019-12-31 | NT$2.21 Billion ≈ $69.75 Million |
NT$156.40 Million ≈ $4.93 Million |
0.071x | +169.06% |
| 2018-12-31 | NT$1.86 Billion ≈ $58.47 Million |
NT$-189.84 Million ≈ $-5.98 Million |
-0.102x | -184.82% |
| 2017-12-31 | NT$2.16 Billion ≈ $68.15 Million |
NT$260.89 Million ≈ $8.22 Million |
0.121x | +435.93% |
| 2016-12-31 | NT$2.12 Billion ≈ $66.77 Million |
NT$-76.09 Million ≈ $-2.40 Million |
-0.036x | +86.25% |
| 2015-12-31 | NT$1.59 Billion ≈ $50.15 Million |
NT$-415.82 Million ≈ $-13.10 Million |
-0.261x | -265.61% |
| 2014-12-31 | NT$1.29 Billion ≈ $40.75 Million |
NT$-92.41 Million ≈ $-2.91 Million |
-0.071x | -16.66% |
| 2013-12-31 | NT$1.39 Billion ≈ $43.93 Million |
NT$-85.39 Million ≈ $-2.69 Million |
-0.061x | +65.70% |
| 2012-12-31 | NT$1.27 Billion ≈ $40.16 Million |
NT$-227.59 Million ≈ $-7.17 Million |
-0.179x | +48.89% |
| 2011-12-31 | NT$1.31 Billion ≈ $41.38 Million |
NT$-458.82 Million ≈ $-14.46 Million |
-0.349x | -- |
About Savior Lifetec
Savior Lifetec Corporation, a specialty injectable company, develops, produces, and supplies sterile active pharmaceutical ingredients and finished dosage formulations. The company provides various carbapenem generic drugs and injections, such as paliperidone palmitate, cetrorelix and ganirelix acetate, plecanatide, prucalopride succinate, and brinzolamide. It offers imipenem and cilastatin, mero… Read more